RxDoctor Payments DataLook up a doctor →

Lindsey Bull

Optometrist · Tulsa, OKNPI 1700132024

Payments from drug & device makers

$218,304in general payments, 2019–2025

Across 779 payments — averaging $280.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$196K
  • Kala Pharmaceuticals, Inc.$15K
  • Biotissue Holdings Inc.$2K
  • Oyster Point Pharma, Inc.$2K
  • Novartis$571
  • Tarsus Pharmaceuticals, Inc.$561
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$24,88011%
  • Speaking & faculty fees$142,73165%
  • Travel & lodging$37,11917%
  • Food & beverage$13,4746%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$218,304 in reported general payments places this provider in the 95th percentile of 714 optometrist providers in Oklahoma.

See all optometrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$281,126
Medicare patients
1,092
Services billed
3,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine254$242,342
LumiganBimatoprost321$180,353
XdemvyLotilaner25$48,779
CombiganBrimonidine Tartrate/Timolol85$35,590
TyrvayaVarenicline Tartrate18$18,368
XiidraLifitegrast11$12,679
Alphagan PBrimonidine Tartrate22$9,788
CequaCyclosporine11$9,473
Prednisolone Acetate272$9,043
VyzultaLatanoprostene Bunod14$7,634
ProlensaBromfenac Sodium16$5,625
Travatan ZTravoprost11$5,278
SimbrinzaBrinzolamide/Brimonidine Tart20$4,755
Dorzolamide-TimololDorzolamide/Timolol/Pf23$4,548
Latanoprost196$3,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$196,222$468,073682 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$561$48,77925 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$79$20,31325 claims
Oyster Point Pharma, Inc.Tyrvaya$1,779$18,36818 claims
Sun Pharmaceutical Industries Inc.Cequa$510$9,47311 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$234$5,62516 claims
NovartisTravatan Z$571$5,27811 claims
AlconSimbrinza$308$4,75520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 optometrist providers in Oklahoma.

Other optometrist in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →